In a notable scientific step, researchers are developing a new technology based on injecting a magnetic fluid into the heart, aiming to reduce the risk of strokes in patients with heart rhythm disorders. This development could open new avenues in cardiology. According to a report published on the ScienceAlert website, citing a recent study, this method targets patients with atrial fibrillation, a common disorder that causes the heart to beat irregularly, increasing the risk of blood clots and strokes. The core problem lies in a small pouch in the heart known as the left atrial appendage, where blood can pool during an irregular heartbeat, leading to clot formation that could travel to the brain. Currently, treatment relies on blood-thinning medications or implanted medical devices to seal this pouch, but these solutions are not ideal: medications can increase the risk of bleeding, while devices do not always provide a complete seal. The new technology takes a different approach, using a catheter to inject the magnetic fluid directly into this pouch. Researchers confirm that years of studies are needed to ensure safety and efficacy, in addition to addressing technical challenges such as the material's effect on MRI scans. The new technology represents an innovative approach to stroke prevention by directly targeting the source of danger within the heart. Although still under development, it reflects how advances in medical engineering can offer promising solutions for one of the most common challenges in heart disease. Within minutes, this fluid transforms into a soft gel-like substance known as a 'magneto-gel,' which seals the pouch completely, with the ability to adapt to its irregular shape. It is believed this method could reduce the chances of blood leakage or clot formation compared to traditional devices. So far, the technology has been tested on animals, with experiments on mice and pigs showing encouraging results. In pig experiments, the material remained stable in the heart for up to 10 months without any leakage or clot formation, and a natural layer of heart tissue formed over it, indicating its biocompatibility. Despite these positive results, the technology is still in its early stages and has not yet been tested on humans. With the help of an external magnetic field, the fluid is guided to completely fill the cavity.
